Here is the design of a clinical trial:

Official Title: PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS SARS-CoV2 (COVID-19)

Included conditions:
- SARS-CoV-2 Infection (COVID-19)

Study Armgroups:
- {'label': 'Colchicine plus symptomatic treatment (paracetamol).', 'type': 'EXPERIMENTAL', 'description': 'Patients in this arm will receive study medication colchicines 0.5 mg orally (PO) twice daily for the first 3 days and then once daily for the last 18 days. If a dose is missed, it should not be replaced.\n\nAll patients should also receive best symptomatic treatment (mainly paracetamol), based on clinical practice.', 'interventionNames': ['Drug: Colchicine plus symptomatic treatment (paracetamol)']}
- {'label': 'Symptomatic treatment', 'type': 'ACTIVE_COMPARATOR', 'description': 'Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).', 'interventionNames': ['Drug: Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)']}

Interventions:
- {'type': 'DRUG', 'name': 'Colchicine plus symptomatic treatment (paracetamol)', 'description': 'Colchicine plus symptomatic treatment (paracetamol).', 'armGroupLabels': ['Colchicine plus symptomatic treatment (paracetamol).']}
- {'type': 'DRUG', 'name': 'Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)', 'description': 'Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).', 'armGroupLabels': ['Symptomatic treatment']}

Primary Outcomes:
- {'measure': 'Number of participants who die due to COVID-19 infection', 'timeFrame': '21 days post-randomization'}
- {'measure': 'Number of participants who require hospitalization due to COVID-19 infection', 'timeFrame': '21 days post-randomization'}

Please estimate the sample size based on the assumption: 
Alpha risk of 5%, beta risk of 80%, and a proportion of 2/1 between the colchicine/placebo groups.
Sample size {14}
        According to the literature [3], an estimated incidence of the primary outcome of 10% in the group treated with placebo and 5% in the group treated with colchicine, in a bilateral contrast, for an alpha risk of 5% and a beta risk of 80%, with a proportion of 2/1 between the colchicine/placebo groups, 636 and 318 are required in the groups treated with colchicine and placebo, respectively.
        Randomization will be stratified by sex and age groups: 60â70, 70â80, and 81 and more years.
        In the current COVID daily cases from the primary health care areas, it is estimated about 5â10 cases of patients to randomize.
        The total number of patients to be included is 954 patients.